The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / A Look Back at Pirquet & Schick’s Influential Serum Sickness Study

A Look Back at Pirquet & Schick’s Influential Serum Sickness Study

November 12, 2020 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In 1905, two pediatricians in Vienna, Austria, published Serum Sickness, a detailed 120-page monograph that was the first to carefully characterize the syndrome.1 The work would go on to become a classic, ultimately helping illuminate many important questions in immunology.

You Might Also Like
  • Rituximab-Induced Serum Sickness Is More Frequent in Autoimmune Diseases
  • Study Reveals Role of IL-17–Secreting CD4+ T Cells in Lupus
  • ACR/ARHP Annual Meeting 2012: Serum Antibodies Offer Useful Clinical Insights into Systemic Sclerosis
Explore This Issue
November 2020
Also By This Author
  • A 52-Year-Old Lupus Paper Remains Important Today

Antitoxin Serum Treatments

In the late 19th century, researchers were working to develop lifesaving antitoxins to certain bacterial diseases.2 Scientists learned how to harvest toxins from bacteria grown in a laboratory. They would then inject horses or other animals with the toxin, and the animals’ immune systems would produce an antitoxin. This could then be collected from the animals, purified and administered as a serum. The antitoxin could successfully neutralize the effects of the original bacterial toxin, such as Corynebacterium diphtheriae.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Tetanus antitoxin was discovered in 1890, and the first case of diphtheria treated with antitoxin was described the following year.2 Such antitoxins soon became common in clinical practice. Clinicians could treat infected persons with them or use them prophylactically in some situations, such as to control disease outbreaks. Anti-serum injections of C. diphtheriae gave patients immunity for around three weeks.4

Dr. Atkinson

Dr. Atkinson

According to John P. Atkinson, MD, the Samuel B. Grant Professor of Medicine at Washington University, St. Louis, School of Medicine, “It was pre-antibiotics. Initially this was the only treatment that had been shown to be effective.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Quickly, it was recognized that though they could save lives, antitoxin serums sometimes caused side effects. Rarely, rapid anaphylactic-type responses were observed after a person was injected with serum.

But another type of response was almost universally observed, initially termed serum exanthema. These self-limited responses were not life threatening and were deemed relatively insignificant. However, the process of coming to understand these responses would contribute to a wider understanding of many important processes in immunology.1,5

Die Serumkrankheit (Serum Sickness)

From 1903 to 1910, Viennese pediatrician Clemens Freiherr von Pirquet, PhB, MD, made very detailed and important observations that helped provide foundational work for the fields of immunology and allergy.5 The studies put forth in Die Serumkrankheit were key components. He wrote the monograph in collaboration with Béla Schick, MD, a Hungarian-born pediatrician with whom he worked at the University of Vienna as lab assistant to Theodore Escherich (known for his work on Escherichia coli).6

Dr. Pirquet

Dr. Pirquet

Arthur M. Silverstein, PhD, an im­munologist, science historian and professor emeritus of ophthalmic immunology at Johns Hopkins School of Medicine, Baltimore, says, “It really was a phenomenal, remarkable piece of work.”

“It is beautifully done,” Dr. Atkinson adds. “It’s very logical and thought provoking and has great attention to detail. You read paragraph after paragraph about issues that came up: How much serum was administered and where, which disease was being treated, patients’ ages, how sick they were, the timing of everything. All these things were carefully documented in what we might call a long clinical article.”

The pair became the first to describe the syndrome in detail and the first to propose that serum sickness arose as a product of an immunological process.5

Clinical Description

The first part of the monograph, “Clinical Aspects of Serum Sickness,” makes up more than half of the text. Here, Pirquet and Schick explored the nature of symptomatology and disease course, referencing case studies of adults and children gathered in their clinic work. They provided detailed graphs showing the timing of specific clinical symptoms as well as laboratory findings, such as leukocyte numbers and blood precipitins.

At the outset, they renamed the syndrome. They wrote:

We have abandoned the expression ‘serum exanthema’ because we think that this name could easily lead to the idea that the rash was the most important symptom of the disease; in its place we have proposed the name ‘serum disease’ or ‘serum sickness.’

Pirquet and Schick were careful to document timing in patients who had never been exposed to anti-sera before:

Most frequently the symptoms of disease start suddenly between 8 and 12 days after the injection … . The period of incubation cannot be explained by the slowness of the absorption of the foreign serum. This serum exerts its anti-toxic effect within a few hours.

Dr. Atkinson confirms this timing co­incides with what we now know about antibody production. “It takes humans five or six days to make antibodies. The IgM comes up, and a few days later the IgG comes up. Then it interacts with the horse serum—immunoglobulin and other proteins, depending on how clean and pure it was. Depending on the ratios and the precipitation reaction, it can form immune deposits in the kidneys and in the joints. Then, as you clear it out within a couple of days, it all goes away.

“The rash and fever were two of the most common problems,” adds Dr. Atkinson. “They described the fevers, how high they were and how long they lasted. Quite a few patients got joint pains, and they go through which joints, whether symmetrical or non-symmetrical. They mention that a few patients had albuminuria.” The pair also noted such symptoms as enlarged lymph nodes and edema, which they documented carefully through tracking patients’ weights.

Pirquet and Schick also made key insights into the relationship of serum dosage to symptom onset, noting:

The intensity of the symptoms also becomes decidedly stronger with an increase in the amount of serum … . The prophylaxis of serum sickness consists in the first place in using the smallest possible amount of serum.

Readministration

In the second section of the monograph, Pirquet and Schick carefully documented the differences in patients receiving a second dose of serum. They observed a large group of children who received diphtheria anti-sera due to exposure on a clinical ward. They then noted the differences between children who had previously received injections and those who had not. Those who had been reinjected often showed an accelerated response, sometimes within 24 hours. They wrote:

This difference could not be due to the antigen (injected serum), as we have shown in our experiments, since the same serum caused different kinds of differently timed reactions, depending on whether it was injected into the organism for the first time or was reinjected. Thus we came to the conclusion that it was the human organism which has become specifically altered, due to the injection of a foreign serum.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions Tagged With: Lost & Found, Serum SicknessIssue: November 2020

You Might Also Like:
  • Rituximab-Induced Serum Sickness Is More Frequent in Autoimmune Diseases
  • Study Reveals Role of IL-17–Secreting CD4+ T Cells in Lupus
  • ACR/ARHP Annual Meeting 2012: Serum Antibodies Offer Useful Clinical Insights into Systemic Sclerosis
  • Serum Interleukin 6 Levels May Predict Presentation of IgG4-Related Disease

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)